Tag: Next-gen tyrosine kinase inhibitor

Home / Next-gen tyrosine kinase inhibitor

Categories

Repotrectinib is approved by the USFDA for ROS1-positive non-small cell lung cancer

The Food and Drug Administration authorized repotrectinib (Augtyro, Bristol-Myers Squibb Company) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) on November 15, 2...
next-gen-tyrosine-kinase-inhibitor

Scan the code